AIMS: Fingolimod is a sphingosine-1-phosphate (S1P) receptor modulator approved for the treatment of the relapsing form of multiple sclerosis (MS). It prevents the egress of lymphocyte subpopulations from lymphoid tissues into the circulation. Here, we explored the broad effects of fingolimod on gene expression in different immune cell subsets. METHODS: Utilizing 150 high-resolution microarrays from Affymetrix, we obtained the transcriptome profiles of 5 cell populations, which were separated from the peripheral blood of MS patients prior to and following oral administration of fingolimod. RESULTS: After 3 months of treatment, significant transcriptome shifts were seen in CD4+ and CD8+ cells, which is mainly attributable to the selective homing of naive T cells and central memory T cells. Although the number of B cells was greatly reduced in the blood of fingolimod-treated MS patients, the analysis of differential expression in CD19+ cells identified only a small set of 42 genes, which indicated a slightly higher frequency of transitional B cells. The transcriptome signatures of CD14+ monocytes and CD56+ natural killer cells were not affected. CONCLUSION: Our study corroborates changes in the composition of circulating immune cells in response to fingolimod and delineates the respective implications at the RNA level. Our data may be valuable for comparing the effects of novel S1P receptor modulating agents, which may be a therapeutic option for patients with secondary progressive MS as well.
AIMS: Fingolimod is a sphingosine-1-phosphate (S1P) receptor modulator approved for the treatment of the relapsing form of multiple sclerosis (MS). It prevents the egress of lymphocyte subpopulations from lymphoid tissues into the circulation. Here, we explored the broad effects of fingolimod on gene expression in different immune cell subsets. METHODS: Utilizing 150 high-resolution microarrays from Affymetrix, we obtained the transcriptome profiles of 5 cell populations, which were separated from the peripheral blood of MSpatients prior to and following oral administration of fingolimod. RESULTS: After 3 months of treatment, significant transcriptome shifts were seen in CD4+ and CD8+ cells, which is mainly attributable to the selective homing of naive T cells and central memory T cells. Although the number of B cells was greatly reduced in the blood of fingolimod-treated MSpatients, the analysis of differential expression in CD19+ cells identified only a small set of 42 genes, which indicated a slightly higher frequency of transitional B cells. The transcriptome signatures of CD14+ monocytes and CD56+ natural killer cells were not affected. CONCLUSION: Our study corroborates changes in the composition of circulating immune cells in response to fingolimod and delineates the respective implications at the RNA level. Our data may be valuable for comparing the effects of novel S1P receptor modulating agents, which may be a therapeutic option for patients with secondary progressive MS as well.
Authors: Rima Haddad; Philippe Guardiola; Brigitte Izac; Christelle Thibault; Jerry Radich; Anne-Lise Delezoide; Claude Baillou; François M Lemoine; Jean Claude Gluckman; Françoise Pflumio; Bruno Canque Journal: Blood Date: 2004-08-26 Impact factor: 22.113
Authors: Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky Journal: Ann Neurol Date: 2011-02 Impact factor: 10.422
Authors: Grace X Y Zheng; Jessica M Terry; Phillip Belgrader; Paul Ryvkin; Zachary W Bent; Ryan Wilson; Solongo B Ziraldo; Tobias D Wheeler; Geoff P McDermott; Junjie Zhu; Mark T Gregory; Joe Shuga; Luz Montesclaros; Jason G Underwood; Donald A Masquelier; Stefanie Y Nishimura; Michael Schnall-Levin; Paul W Wyatt; Christopher M Hindson; Rajiv Bharadwaj; Alexander Wong; Kevin D Ness; Lan W Beppu; H Joachim Deeg; Christopher McFarland; Keith R Loeb; William J Valente; Nolan G Ericson; Emily A Stevens; Jerald P Radich; Tarjei S Mikkelsen; Benjamin J Hindson; Jason H Bielas Journal: Nat Commun Date: 2017-01-16 Impact factor: 14.919
Authors: Cath Tyner; Galt P Barber; Jonathan Casper; Hiram Clawson; Mark Diekhans; Christopher Eisenhart; Clayton M Fischer; David Gibson; Jairo Navarro Gonzalez; Luvina Guruvadoo; Maximilian Haeussler; Steve Heitner; Angie S Hinrichs; Donna Karolchik; Brian T Lee; Christopher M Lee; Parisa Nejad; Brian J Raney; Kate R Rosenbloom; Matthew L Speir; Chris Villarreal; John Vivian; Ann S Zweig; David Haussler; Robert M Kuhn; W James Kent Journal: Nucleic Acids Res Date: 2016-11-29 Impact factor: 16.971
Authors: Bibiana Quirant-Sánchez; José V Hervás-García; Aina Teniente-Serra; Luis Brieva; Ester Moral-Torres; Antonio Cano; Elvira Munteis; María J Mansilla; Silvia Presas-Rodriguez; Juan Navarro-Barriuso; Cristina Ramo-Tello; Eva M Martínez-Cáceres Journal: CNS Neurosci Ther Date: 2018-04-15 Impact factor: 5.243
Authors: Qi Wu; Elizabeth A Mills; Qin Wang; Catherine A Dowling; Caitlyn Fisher; Britany Kirch; Steven K Lundy; David A Fox; Yang Mao-Draayer Journal: JCI Insight Date: 2020-02-13
Authors: G Sferruzza; F Clarelli; E Mascia; L Ferrè; L Ottoboni; M Sorosina; S Santoro; L Moiola; V Martinelli; G Comi; F Martinelli Boneschi; M Filippi; P Provero; Federica Esposito Journal: Mol Neurobiol Date: 2021-06-28 Impact factor: 5.590